Heart Protection Study [3] (multiple letters)

Lancet

Volumn 361, Issue 9356, 2003, Pages 528-530

  Metcalfe, R Scott ^a   Dawson, Sandy ^b   Milne, Richard J ^c   Poli, Andrea ^d   Catapano, Alberico ^d   Wilmshurst, Peter ^e   Collins, Rory ^f   Armitage, Jane ^f   Parish, Sarah ^f   Sleight, Peter ^f   Peto, Richard ^f   Trewby, Peter ^g   Yusuf, Salim ^h  

^a Pharmaceutical Management Agency   (New Zealand)

^b MINISTRY OF HEALTH   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF MILAN   (Italy)

^e ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; PLACEBO;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HYPERCHOLESTEROLEMIA; NOTE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICS; RISK; STATISTICAL ANALYSIS; EPIDEMIOLOGY; METHODOLOGY;

CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS; RISK REDUCTION BEHAVIOR; SIMVASTATIN; TREATMENT OUTCOME; DATA INTERPRETATION, STATISTICAL; RISK; BIAS (EPIDEMIOLOGY); PLACEBOS; RESEARCH DESIGN;

EID: 0037425746     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12472-5     Document Type: Letter

References (0)